IP Library Granted Patent US 8,383,155
Granted Patent B2
US 8,383,155 · App. 13/212,679 · Granted Feb 26, 2013

Swellable dosage form comprising gellan gum

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,155
App. No.
13/212,679
Granted
Feb 26, 2013
Kind
B2
Abstract

A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C. In one embodiment of the invention, the particulate matter can be molded into a desired shape or pressed onto a dispensing unit such as a spoon.

Claims (25)

1. A solid dosage form for oral administration comprising one or more active substances blended with a swellable vehicle comprising 20-80% by weight of a swellable gellan gum, or swellable mixture of gellan gums, arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less, the composition swells and/or gels;

wherein the gellan gum is acylated within a degree of up to 4 per every two repeats of the glucose-rhamnose-glucose-glucoronic acid unit of the polymer, and

the swellable vehicle further comprises a hydrophilic agent selected from the group consisting of electrolytes, organic acids and osmotic agents, and mixtures thereof, that improves swelling of the gellan gum; and

the texture of the swelled composition being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C. by a test method wherein 22-88 g test material is accurately weighed and placed in a 500 ml beaker, 500 ml tap water is added, the contents are mixed until all the test material is dispersed/dissolved, and after about 5 minutes the viscosity and temperature are measured by centering the Viscometer spindle in the test sample container and immersing the spindle to the mid-point of the shaft's narrow portion.

2. A solid dosage form according to claim 1 , in the form of a unit dosage form.

3. A solid dosage form according to claim 2 , in the form of granulates contained in a capsule, cachet or sachet.

4. A solid dosage form according to claim 2 , in the form of a tablet.

5. A solid dosage form according to claim 4 , wherein the tablet is produced by low-pressure compression, extruding, molding or calendaring.

6. A solid dosage form according to claim 2 , in the form of a tape or laminate.

7. A solid dosage form according to claim 2 , provided in a dispensing unit incorporating the solid dosage form.

8. A solid dosage form according to claim 7 , wherein the dispensing unit is a spoon.

9. A dispensing unit for oral administration comprising a solid dosage form according to claim 1 .

10. A dispensing unit according to claim 9 , in unit dosage form.

11. A dispensing unit according to claim 9 , wherein one or more active substances and the swellable vehicle are adhered or glued to a surface of the dispensing unit.

12. A dispensing unit according to claim 11 , wherein the one or more active substances and the swellable vehicle are glued to a surface of the dispensing unit with a glue that comprises one or more components in liquid form or in solution selected from the group consisting of sugar alcohols, sugars, polyvinylpyrrolidone (PVP), and gums.

13. A dispensing unit according to claim 12 , wherein the glue comprises a mixture of PVP and glycerol.

14. A dispensing unit according to claim 9 , having a concave surface.

15. A dispensing unit according to claim 9 in the form of a spoon.

16. A dispensing unit according to claim 12 , in the form of a spoon.

17. A dispensing unit according to claim 13 , in the form of a spoon.

18. A kit comprising a solid dosage form according to claim 2 , and instructions to combine the solid dosage form with a measured amount of water prior to administration.

19. A kit comprising a solid dosage form according to claim 3 , and instructions to put the granulates into a measured amount of water prior to administration.

20. A kit comprising a solid dosage form according to claim 4 , and instructions to put the tablet into a measured amount of water prior to administration.

21. A kit comprising a solid dosage form according to claim 7 , and instructions to add a measured amount of water to the dispensing unit prior to administration.

22. A kit comprising a solid dosage form according to claim 8 , and instructions to add a measured amount of water to the spoon prior to administration.

Assignments (10)
SECURITY INTEREST Recorded Nov 8, 2022
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: TEAL MIDCO HOLDINGS, L.P.
Reel/Frame 061698/0541 →
SECURITY INTEREST Recorded Sep 22, 2020
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: CRESCENT AGENCY SERVICES LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 053849/0967 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2020
From: U.S. BANK NATIONAL ASSOCIATION
To: ZYLA LIFE SCIENCES, F/K/A EGALET CORPORATION; ZYLA LIFE SCIENCES US INC., F/K/A EGALET US, INC.; EGALET LIMITED
Reel/Frame 053411/0496 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded May 21, 2020
From: CANTOR FITZGERALD SECURITIES, AS AGENT AND AS COLLATERAL AGENT
To: ZYLA LIFE SCIENCES (F/K/A EGALET CORPORATION); ZYLA LIFE SCIENCES US INC. (F/K/A EGALET US, INC.); EGALET LIMITED
Reel/Frame 052740/0025 →
RELEASE OF SECURITY INTEREST Recorded Sep 13, 2019
From: U.S. BANK NATIONAL ASSOCIATION
To: EGALET CORPORATION; EGALET US, INC.; EGALET LTD
Reel/Frame 050367/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2019
From: EGALET LTD
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 049505/0851 →
RELEASE OF SECURITY INTEREST Recorded Apr 12, 2019
From: CANTOR FITZGERALD SECURITIES, AS AGENT AND AS COLLATERAL AGENT
To: EGALET CORPORATION; EGALET LIMITED; EGALET US, INC.
Reel/Frame 048869/0749 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2019
From: EGALET CORPORATION; EGALET US, INC.; EGALET LIMITED
To: CANTOR FITZGERALD SECURITIES, AS COLLATERAL AGENT
Reel/Frame 050152/0828 →
CHANGE OF ADDRESS Recorded Oct 3, 2016
From: EGALET LTD.
To: EGALET LTD.
Reel/Frame 040293/0249 →
SECURITY INTEREST Recorded Aug 31, 2016
From: EGALET CORPORATION; EGALET US, INC.; EGALET LTD
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 039600/0791 →